All In Biotech

Free tool

FAERS Monitor: Airsupra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214070 or its brand name (Airsupra, Albuterol Sulfate, Budesonide). Reports on generic versions are filed under their own applications.

Reports

1,599

Serious

319

20% of reports

Hospitalization

114

Death reported

18

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • device delivery system issue422
  • product dose omission issue261
  • asthma197
  • dyspnoea183
  • device malfunction179
  • wrong technique in device usage process168
  • drug ineffective137
  • wrong technique in product usage process134
  • incorrect dose administered by device130
  • device use issue128
  • cough110
  • incorrect dose administered95
  • drug dose omission by device88
  • product use issue84
  • device defective66

Reports by year received

View as table
YearReports
20204
20211
20227
202314
2024208
2025784
2026581

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,560 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
device delivery system issueSignal422205.9189.684,633
device use issueSignal12896.982.111,981
incorrect dose administered by deviceSignal13065.655.68,170
device defectiveSignal6650.339.73,129
wrong technique in device usage processSignal16847.541.17,587
device malfunctionSignal17933.629.35,632
asthmaSignal19723.020.14,132
drug dose omission by deviceSignal8814.812.11,121
product dose omission issueSignal26111.710.52,573
wrong technique in product usage processSignal1348.77.4914
product use issueSignal845.94.8338
incorrect dose administeredSignal955.54.5347
coughSignal1105.24.3370
dyspnoeaSignal1834.33.7464
drug ineffective1371.41.214

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.